GSK2018682 FTIH in Healthy Volunteers

Summary

This protocol describes the first administration of GSK2018682 to humans. The study will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single ascending doses of GSK2018682. The study will also provide preliminary evidence of the potential therapeutic dose-range by measuring the inhibitory effect of GSK2018682 on total lymphocyte counts.

Timeline

Start

2010-05-21

Primary completion

2010-12-20

Completion

2010-12-20

Drugs

Indications